30.98  -1.98 (-6.01%)		09-01 16:00
Open: 32.74 High: 32.95 Volume: 45,233		Pre. Close: 32.96 Low: 30 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	44.24	1-year :	51.71
Resists	First :	37.88	Second :	44.27
Pivot price	38.89
Supports	First :	27.54	Second :	22.91
MAs	MA(5) :	35.71	MA(20) :	39.45
	MA(100) :	24.07	MA(250) :	17.62
MACD	MACD :	1	Signal :	2.7
%K %D	K(14,3) :	13.3	D(3) :	22.7
RSI	RSI(14): 37.6
52-week	High :	44.27	Low :	7.93

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ YARW ] has closed below the lower bollinger band by 9.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ YARW ] is to continue within current trading range. It is unclear right now based on current values. 128.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	33 - 33.23	33.23 - 33.41
Low:	29.44 - 29.73	29.73 - 29.95
Close:	30.57 - 30.97	30.97 - 31.28

Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

Thu, 13 Aug 2026
Yarrow Bioscience (YARW) Financials 2026 - Income Statement and Balance Sheet - MarketBeat

Thu, 13 Aug 2026
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance

Thu, 30 Jul 2026
YARW | Yarrow Bioscience, Inc. Common Stock Data, Price & News - Quiver Quantitative

Tue, 28 Jul 2026
Yarrow Bioscience, Inc. Financial Statements – NASDAQ:YARW - TradingView

Tue, 28 Jul 2026
Cost of goods sold of Yarrow Bioscience, Inc. – NASDAQ:YARW - TradingView

Tue, 28 Jul 2026
Yarrow Bioscience closes VYNE merger and $200 million financing - Quiver Quantitative

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	3 (M)
Shares Float	2 (M)
Held by Insiders	4.4 (%)
Held by Institutions	60.7 (%)
Shares Short	13 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	1 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	147.7

Dividend	20.1
Forward Dividend	0
Dividend Yield	64.8%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.